In June 2020, BSV formed a strategic alliance with LaVoieHealthScience in order to enhance BSV's capabilities to communicate value. <read more here>                     In May 2020, BSV entered into a strategic alliance with FCF Fox Corporate Finance to support funding activities. <read more here>                    
                           COVID-19 Portal               Home      About      Team      Clients      Publications      Downloads      News      Career      Contact

  Bioscience Valuation's unique approach to portfolio management clearly enhanced the value of our R&D pipeline.

Prof. Dr. Klaus Nickisch, CSO Evestra Inc., formerly Head of Project Management at Bayer Schering Pharma AG


Core Services
  Financial Valuation
  Commercial Assessment &

  R&D Risk Analysis &
Productivity Increase

  Portfolio Management
  Investment Decisions
  Partnering / Licensing
  Corporate Finance / M&A

Special Expertise
  Economic Modeling
of Healthcare Systems

  Assessing the Economics
of Personalized Medicine

Comprehensive Support
  Corporate Partnership Program

  Market Model
  R&D Risk Model
  Valuation Model

Bioscience Valuation's Valuation Model
Customers may license Bioscience Valuation's programs for their own use. Bioscience Valuation's Valuation Model provides unparalleled analysis capabilities that include, among others, the following key features:
  • intuitive use and interpretation of results,
  • sensitivity analyses for the most important input variables,
  • ability to determine the expected value increase as the project progresses during development,
  • guidance on discount rates,
  • easily used together with Bioscience Valuation's Market and R&D Risk models for comprehensive analysis.

Bioscience Valuation offers training courses for clients who license its valuation model.

Please contact us for receiving further information, or to order the model.

This website uses cookies to ensure you get the best experience on our website.
Privacy Policy